News

New immuno-pet tracer superior to FDG PET in predicting PD-L1 expression in head and neck cancer
PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer ...
Medscape Reference8d
PD-L1 Did Not Predict Immunotherapy Benefit in Cervical Cancer
A post hoc analysis of the BEATcc trial showed that atezolizumab plus chemotherapy and bevacizumab provided clinical benefit ...
Business Wire3mon
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications - Business Wire
PD-L1 is a critical biomarker for potential response to anti-PD-1 therapies, which are revolutionizing the treatment of cancer. Pathology labs play an important role in informing treatment decisions.
Yahoo Finance1mon
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation - Yahoo Finance
About APVO711. Novel Mechanism: APVO711 is a bispecific antibody targeting PD-L1 × CD40-combining checkpoint inhibition with immune activation in a single molecule. Designed for Potency: Unlike ...
FDA approves pembrolizumab for resectable head and neck cancer with PD-L1 expression
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...
Medscape9mon
Ivonescimab Tops Pembro in Advanced PD-L1-Positive NSCLC - Medscape
The investigational PD-1/VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC.
The American Journal of Managed Care4mon
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Tislelizumab, combined with chemotherapy, is now FDA-approved for first-line treatment of unresectable or metastatic ESCC with PD-L1 expression. The phase 3 RATIONALE-306 study demonstrated ...
Cure Today3mon
Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors
Additionally, six PD-L1–resistant patients with stable disease remain on treatment past 12 or more weeks, with tumor reductions ranging from 0% to 17%, suggesting durable disease control in a subset ...
FierceBiotech11mon
Incyte drops two PD-L1 drugs as part of 2nd pipeline clear-out - Fierce Biotech
Incyte drops pair of PD-L1 drugs as part of 2nd pipeline clear-out this year. By James Waldron Jul 30, 2024 8:14am. Incyte PD-L1 checkpoint inhibitors solid tumor. For ...
Morningstar1mon
Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer - Morningstar
Clinical Trials Demonstrate Monitoring PD-L1 Upregulation Using LifeTracDx Blood Test Could Support New Treatment Path for Metastatic Triple Negative Breast Cancer. PR Newswire.
FiercePharma2mon
Summit stock falls as Akeso shares bispecific overall survival data
In announcing (Chinese) ivonescimab’s Chinese approval in first-line PD-L1-positive non-small cell lung cancer on Friday, Akeso noted that the bispecific drug slashed the risk of death by 22.3% ...
Healio9mon
FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy - Healio
The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.The agent (Tecentriq Hybreza, Genentech) is the first subcutaneous anti-PD-L1 cancer immunotherapy approved in the ...